← Back to Clinical Trials
Recruiting Phase 4 NCT05968885
NCT05968885 Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity
◆ AI Clinical Summary
Plain-language summary for patients
| NCT ID | NCT05968885 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Mackay Memorial Hospital |
| Condition | Urinary Bladder, Overactive |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2021-10-01 |
| Primary Completion | 2026-06-30 |
Trial Parameters
Condition Urinary Bladder, Overactive
Sponsor Mackay Memorial Hospital
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 300
Sex FEMALE
Min Age 20 Years
Max Age 90 Years
Start Date 2021-10-01
Completion 2026-06-30
All Conditions
Interventions
Intradetrusor Botox® (onabotulinumtoxinA) injectionCombine Mirabegron and Solifenacin.
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
To investigates the effects of botulinum toxin type A bladder injection compared to combined pharmacotherapy with Mirabegron and Solifenacin.
Eligibility Criteria
Inclusion Criteria: * Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with either anti-muscarinics or β3-adrenoceptor agonists were enrolled for prospective study Exclusion Criteria: * Postvoid urine retention before treatment
Related Trials
NCT05968885
Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Det
View Trial →
NCT06479720
Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Ove
View Trial →
NCT06201013
Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology